Psoriatic arthritis

被引：18

作者：

Wollina, Uwe ^{[1
]}

Unger, Leonore ^{[2
]}

Heinig, Birgit ^{[3
]}

Kittner, Thomas ^{[4
]}

机构：

[1] Tech Univ Dresden, Dept Dermatol & Allergol, Dresden, Germany

[2] Tech Univ Dresden, Dept Rheumatol, Dresden, Germany

[3] Tech Univ Dresden, Ctr Phys Therapy & Rehabil, Dresden, Germany

[4] Tech Univ Dresden, Dept Radiol, Hosp Dresden Friedrichstadt, Acad Teaching Hosp, Dresden, Germany

来源：

DERMATOLOGIC THERAPY | 2010年 / 23卷 / 02期

关键词：

biologics; dactylitis; DMARDS; enthesitis; psoriatic arthritis; treatment; uveitis; NECROSIS-FACTOR-ALPHA; PLACEBO-CONTROLLED TRIAL; NERVE GROWTH-FACTOR; LONG-TERM TREATMENT; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; RHEUMATIC-DISEASES; ADALIMUMAB EFFECTIVENESS; INFLIXIMAB TREATMENT; SYNOVIAL-CELLS;

D O I：

10.1111/j.1529-8019.2010.01306.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Psoriatic arthritis (PSA) is an entity of inflammatory joint disease associated with psoriasis. PSA belongs to the heterogeneous group of seronegative spondylarthropathies. Both peripheral joints and axial skeleton can be affected in a characteristic pattern. In addition to that, enthesitis and dactylitis are important extracutaneous manifestations. Uveitis anterior is temporarily seen in about one quarter of PSA patients. There is a closer relationship of nail and joint disease. This review provides data on drug and physical treatment options. In particular DMARDS and inhibitors of tumor necrosis factor alpha are established therapies with importance for quality of life and long term outcome. New drugs are tested in various trials.

引用

页码：123 / 136

页数：14

共 99 条

[1]

ABUSHAKRA M, 1995, J RHEUMATOL, V22, P241

[2]

ADLER S, 2000, PNF PRACTICE

[3]

ALIBERT JL, 1818, PRECIS THEORIQUE PRA, V2, P21

[4] Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation [J].

Antoni, C ;

Dechant, C ;

Lorenz, PDHM ;

Wendler, J ;

Ogilvie, A ;

Lueftl, M ;

Kalden-Nemeth, D ;

Kalden, JR ;

Manger, B .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (05) :506-512

[5] Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [J].

Antoni, CE ;

Kavanagh, A ;

Kirkham, B ;

Tutuncu, Z ;

Burmester, GR ;

Schneider, U ;

Furst, DE ;

Molitor, J ;

Keystone, E ;

Gladman, D ;

Manger, B ;

Wassenberg, S ;

Weier, R ;

Wallace, DJ ;

Weisman, MH ;

Kalden, JR ;

Smolen, J .

ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1227-1236

[6]

Antoni CE, 2008, J RHEUMATOL, V35, P869

[7]

ATTENO M, 2010, CLIN RHEUMA IN PRESS

[8]

BAZIN P, 1869, THEORIQUES CLIN AFFE, P154

[9]

Benjamin M, 2009, ADV EXP MED BIOL, V649, P57

[10]

BOSSERT FP, 2003, ELECTROTHERAPY LIGHT

← 1 2 3 4 5 6 7 8 9 10 →